NeuroSense (NASDAQ: NRSN) shares surge over 400% as they receive clearance from the FDA to initiate a pharmacokinetic study of PrimeC in healthy adult subjects.
NeuroSense (NASDAQ: NRSN) shares surge over 400% as they receive clearance from the FDA to initiate a pharmacokinetic study of PrimeC in healthy adult subjects.
© NeuroSense Therapeutics 2021 All Rights Reserved | Site by: Webnoise | Privacy Policy | Terms | Accessibility